» Articles » PMID: 27221981

Notch2 is a Crucial Regulator of Self-renewal and Tumorigenicity in Human Hepatocellular Carcinoma Cells

Overview
Journal Oncol Rep
Specialty Oncology
Date 2016 May 26
PMID 27221981
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The Notch pathway plays an important role in both stem cell biology and cancer. Notch2 was reported to be upregulated in human hepatocellular carcinoma (HCC) tissues. However, the biological function of Notch2 in human HCC cells has not yet been documented. The aim of this study was to investigate its possible function on the progression of human HCC cells. The expression of Notch2 was detected in four human HCC cell lines by western blotting. Next, Notch2 was knocked down by small interference RNA (siRNA) in human HCC cells. The role of Notch2 in human HCC cells was investigated by cell proliferation assay, colony formation assay, chemoresistance and xenograft formation assay. In the present study, western blotting revealed that the expression of Notch2 was upregulated in human HCC cell lines. Genetic depletion of Notch2 in HCC cells not only resulted in significantly inhibited proliferation, cell cycle progression and colony formation ability but also increased its sensitivity to 5-fluorouracil (5-FU) compared with controls. In addition, upregulation of Notch2 was discovered in CD90 positive HCC cells, CD90 is a marker of hepatic stem cells. Most importantly, knockdown of Notch2 in HCC cells impaired the tumor formation in vivo. Taken together, our findings indicate that Notch2 may confer stemness properties in HCC; downregulation of Notch2 inhibited the proliferation and tumor formation of HCC cells and increase their sensitivity to 5-FU, suggesting Notch2 as a potential therapeutic target for HCC.

Citing Articles

DNAJB1-PKAc Kinase Is Expressed in Young Patients with Pediatric Liver Cancers and Enhances Carcinogenic Pathways.

Fleifil Y, Gulati R, Jennings K, Miethke A, Bondoc A, Tiao G Cancers (Basel). 2025; 17(1).

PMID: 39796711 PMC: 11720578. DOI: 10.3390/cancers17010083.


Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies.

Montagner A, Arleo A, Suzzi F, DAssoro A, Piscaglia F, Gramantieri L Biomolecules. 2025; 14(12.

PMID: 39766289 PMC: 11674819. DOI: 10.3390/biom14121581.


Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.

Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S Signal Transduct Target Ther. 2024; 9(1):128.

PMID: 38797752 PMC: 11128457. DOI: 10.1038/s41392-024-01828-x.


Comprehensive characterization of coding and non-coding single nucleotide polymorphisms of the Myoneurin (MYNN) gene using molecular dynamics simulation and docking approaches.

Mou S, Sultana T, Chatterjee D, Faruk M, Hosen M PLoS One. 2024; 19(1):e0296361.

PMID: 38165846 PMC: 10760682. DOI: 10.1371/journal.pone.0296361.


Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma.

Laface C, Ranieri G, Maselli F, Ambrogio F, Foti C, Ammendola M Cancers (Basel). 2023; 15(3).

PMID: 36765612 PMC: 9913568. DOI: 10.3390/cancers15030654.